B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
RAPP
Rapport TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+46.2
Score
AI commentary
Sentiment is cautious rather than outright bullish: Rapport has credible primary-source support for RAP-219's Phase 3 path and a stronger cash position than many micro/mid-cap biotech peers, but the current setup is still mainly a filing-backed monitoring story with limited fresh external confirmation since the March 10, 2026 filings and a negative deterministic directional prior [#10-K-2026-03-10] [#8-K-2026-03-10].
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 2026 filing to confirm burn and runway after Phase 3 prepHigh impact
The next quarterly filing should show whether cash burn is tracking consistently with management's statement that $490.5 million of cash, cash equivalents and short-term investments at December 31, 2025 can fund operations into the second half of 2029 as RAP-219 moves toward late-stage development [#10-K-2026-03-10] [#8-K-2026-03-10].
2026-06-30eventRAP-219 Phase 3 program initiation in focal onset seizuresHigh impact
The clearest forward catalyst is execution against management's stated plan to initiate two parallel global Phase 3 trials in the second quarter of 2026 after the December 2025 end-of-Phase-2 FDA meeting supported advancement into Phase 3; a visible start would modestly de-risk the story, while any slip would likely hurt sentiment [#10-K-2026-03-10].
2026-12-31catalystSustained Phase 3 enrollment and external validation of RAP-219 platform valueHigh impact
Longer term upside depends on Rapport showing it can enroll and run the two planned RAP-219 Phase 3 studies at scale while converting the Tenacia Greater China deal into tangible economics beyond the disclosed $20 million upfront and potential milestone structure; this is meaningful but still early and execution-heavy [#10-K-2026-03-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology